2:50 PM
 | 
Mar 22, 2017
 |  BC Extra  |  Financial News

Semma receives JDRF investment

Cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.) said it received an undisclosed investment from the JDRF T1D Fund. Semma CEO Robert Millman told BioCentury that the investment, which took the form of a convertible note, is part of a...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >